Amylyx Pharmaceuticals Inc (AMLX)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AMLX
Amylyx Pharmaceuticals Inc
$29.86
-6.10%
HEALTHCARE · Cap: $4.09B
TAK
Takeda Pharmaceutical Co Ltd ADR
$21.12
+1.34%
HEALTHCARE · Cap: $67.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates -705749853% more annual revenue ($4.69T vs $-665,000). TAK leads profitability with a 0.9% profit margin vs 0.0%. TAK earns a higher WallStSmart Score of 56/100 (C).
AMLX
Avoid33
out of 100
Grade: F
TAK
Buy56
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Generating 212.6B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 24.5%
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
ROE of 5.2% — below average capital efficiency
0.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 9.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Profit Margin, Operating Margin.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, Profit Margin, P/E Ratio. A P/E of 300.3x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
TAK carries more volatility with a beta of 0.08 — expect wider price swings.
TAK is growing revenue faster at 6.7% — sustainability is the question.
TAK generates stronger free cash flow (212.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (56/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?